This over activity can be mitigated by RAAS inhibitors such as ACE inhibitors (ACEIs), AT1R blockers (ARBs), and mineralocortocoid receptor inhibitors (MCRIs), commonly used in managing hypertension, heart failure, cardiac myopathies, and delaying the progression of cardiac/renal pathologies (Arendse et al., 2019) as well as by EGFR inhibitors (Qian et al., 2016; Rintala et al., 2016). This evidence concerns the gene EGFR and Hypertension.